Variable effects of 3 different chondroitin sulfate compounds on human osteoarthritic cartilage/chondrocytes: relevance of purity and production process.
OBJECTIVE
During osteoarthritis (OA), the altered metabolism of cartilage involves proinflammatory factors and matrix metalloprotease (MMP) activity. Studies showed that chondroitin sulfate (CS) may exert a positive effect on the cartilage. Because of differences in CS in terms of purity and the production/purification process, we compared the effects of 3 different types of CS on human OA cartilage.


METHODS
Three types of CS were tested: CS1 (porcine, purity 90.4%), CS2 (bovine, purity 96.2%), and CS3 (bovine, purity 99.9%). Treatment with CS at 200 and 1000 microg/ml was performed on human OA cartilage explants in the presence/absence of interleukin 1ss (IL-1ss), and the protein modulations of factors including prostaglandin E(2) (PGE(2)), IL-6, and MMP-1 measured by ELISA. The CS effect on the expression of collagen type II was also investigated on OA chondrocytes using quantitative polymerase chain reaction.


RESULTS
In the presence of IL-1ss, CS2 at 1000 microg/ml significantly inhibited IL-6 and PGE(2) production, and CS3 at 200 microg/ml markedly reduced the level of IL-6. CS1 was much less efficient at reducing the catabolic markers and in the absence of IL-1ss, it significantly increased IL-6 and MMP-1. IL-1ss significantly inhibited the gene expression level of collagen type II; only CS3 was able to limit this inhibition. CS1, in the presence or absence of IL-1ss, further markedly decreased collagen type II expression.


CONCLUSIONS
Our data indicate that among the 3 tested CS, CS1 increased production of some catabolic pathways and inhibited the gene expression level of collagen type II. Our study provides new information in the context of prescribing CS for alleviating OA symptoms, as the purity and/or production/purification of the CS compound could orient the current OA disease process toward increased catabolic pathways.
Tat
Steeve Kwan
SK
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre, Notre-Dame Hospital, Montreal, Quebec H2L 4M1, Canada.
Pelletier
Jean-Pierre
JP
Mineau
François
F
Duval
Nicolas
N
Martel-Pelletier
Johanne
J
D000368:Aged; D000818:Animals; D002356:Cartilage / Q000187:drug effects* / Q000378:metabolism; D002417:Cattle; D002478:Cells, Cultured; D019902:Chondrocytes / Q000187:drug effects* / Q000378:metabolism; D002809:Chondroitin Sulfates / Q000032:analysis / Q000096:biosynthesis / Q000494:pharmacology*; D024043:Collagen Type II / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D053583:Interleukin-1beta / Q000494:pharmacology; D015850:Interleukin-6 / Q000378:metabolism; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000378:metabolism*; D013552:Swine
D024043:Collagen Type II; D053583:Interleukin-1beta; D015850:Interleukin-6; D002809:Chondroitin Sulfates; D020781:Matrix Metalloproteinase 1; D015232:Dinoprostone